GA will be a world leading molecular diagnostic company with core competence in mapping of microbiota, utilizing the GA-map™ technology to develop IVD tests in all diseases where microbiota is involved.

Business model

Develop, document and manufacture, marketing IVD products meeting regulatory requirements worldwide. These products will be commercialized worldwide through third parties and through sales from our service lab.

Value proposition

GA will build high margin business in rapid growing market by developing innovative solution for better patient treatment.

New diagnostic test in a huge and growing market

Gut microbiota is considered as a new organ due to its newly revealed importancy for healh.

GA has developed the first CE marked diagnostic test for detecting dysbiosis (bacterial imbalance) in patients with IBS (irritable bowel syndrome)
In IBS it is estimated that 70% of the patients do suffer from dysbiosis and they should probably be treated differently from non-dysbiotic IBS patients.


An increasing number of serious disorders are linked to a distortion in the microbial balance in the human gut, referred to as dysbiosis:

-Irritable bowel syndrome (IBS)
-Chrons Disease + Ulcerative Colitis (jointly: IBD)
-Diabetes type II
-Allergies and gluten intolerance
-Autoimmune diseases like multiple sclerosis and rheumatoid arthritis
-And others….

The relationship of dysbiosis to disease is now one of the major fields of medical research. Characterizing microbiota is also vital for accurate diagnosis and treatment.

Until now there has been no documented dysbiosis test available.

Genetic Analysis has developed and launched the first commercial test for IBS in the European and US market (for research use) – the GA-map™ Dysbiosis Test.